Chemotherapy and cancer drugs
The latest chemistry news and research on chemotherapy and cancer drugs, including antibodies and immuno-oncology, from the Royal Society of Chemistry's magazine, Chemistry World
-
WebinarDeveloping a CITK protein degrader using the QuicTPD™ platform
Join us on 18 November to learn about the latest technology to accelerate the design of cancer treatments
-
ResearchAI tools turned to creating designer proteins for personalised cancer therapies and antibiotics
Powerful new class of AI model could dramatically speed up process of producing new kinds of drug candidates
-
BusinessMerck KGaA to buy cancer specialist SpringWorks
$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries
-
NewsFears grow over the future of mRNA vaccine research in the US
Researchers working on mRNA vaccines fear federal funding might be halted, with many looking to move projects abroad
-
FeatureThe promise of drugs that send proteins to the shredder
Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to strategic discovery
-
ResearchAI tool learns to build molecules fragment by fragment
Software tasked with designing a type-II kinase inhibitor suggests 97 candidates in 10 minutes, three of which were both synthesisable and effective at micromolar and nanomolar concentrations
-
WebinarEmerging routes to new therapeutics: Highlights from winning Horizon Prize teams
Discover how new therapeutics have the potential to address unmet medical needs
-
WebinarThe science and promise of liquid biopsies: improving cancer treatment
Learn how liquid biopsies are being used to identify cancer and improve patient outcomes
-
FeatureThe high price of a suntan
Skin cancer is on the rise in many countries around the world, but so are the methods to treat it. Bárbara Pinho reports
-
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
FeatureMore than a mirror-image: left-handed nucleic acids
Now a biological reality, researchers are starting to figure out the many roles of left-handed nucleic acids such as Z-DNA – from immunity to controlling our genetics. Rachel Brazil reports
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
ResearchAlphaFold works with other AI tools to go from target to hit molecule in 30 days
End-to-end AI drug discovery process predicts potential inhibitors for a protein implicated in liver cancer
-
ResearchRadium chelator researchers working to improve targeted cancer therapies
Oak Ridge National Lab team investigate factors underpinnning Ra2+ complex stability and selectivity in attempt to expand the therapeutic utility of radium-223
-
ResearchYeast engineered to ferment sugars into chemotherapy drug precursors
Semisynthesis offers new route to anticancer drug vinblastine
-
ResearchLight-activated cancer treatment uses tumour-targeting enzymes to cut side effects
Enzymatic activation of a photosensitive prodrug in cancerous cells shows promise in mice
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
ResearchClick chemistry uses endogenous acrolein to activate cancer prodrug
Strategy could reduce chemotherapy side effects by selecting for cancerous cells